Syndax Pharmaceuticals Crecimiento futuro
Future controles de criterios 6/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Syndax Pharmaceuticals de 68.5% y 30.3% por año respectivamente. Se prevé que el BPA crezca en un 68.9% al año. Se espera que la rentabilidad financiera sea de 35.3% en 3 años.
Información clave
68.5%
Tasa de crecimiento de los beneficios
68.89%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.4% |
| Tasa de crecimiento de los ingresos | 30.3% |
| Rentabilidad financiera futura | 35.30% |
| Cobertura de analistas | Good |
| Última actualización | 19 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 20
SNDX: Upcoming IPF Data Readout May Unlock Underappreciated Upside Potential
Analysts have reduced the Syndax Pharmaceuticals fair value estimate from $56.00 to approximately $53.54, reflecting a combination of slightly lower price targets and updated views on growth, profitability, and appropriate P/E levels across recent research updates. Analyst Commentary Recent Street research on Syndax Pharmaceuticals shows a mix of target price increases and reductions, with the overall effect being a modest pullback in the aggregated fair value estimate.Artículo de análisis • May 05
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders are probably feeling a little disappointed, since its shares...
Actualización de narrativa • Apr 29
SNDX: Upcoming Pulmonary Fibrosis Readout Will Refine Risk Profile And Long-Term Upside
The updated analyst price target for Syndax Pharmaceuticals edges up by about $1 to $39.50 as analysts factor in new Street research that balances recent target cuts with higher targets and fresh Buy initiations. Analyst Commentary Street research on Syndax Pharmaceuticals has been active, with several firms adjusting price targets and ratings in recent weeks.
Actualización de narrativa • Apr 14
SNDX: MAXPIRe IPF Data Will Drive Future Upside Versus Execution Risks
The updated analyst price target for Syndax Pharmaceuticals now stands at $28.00. The adjustment is based on recent Street research that weighs higher targets from several firms against more cautious revisions, as analysts reassess the risk profile and potential of the Revuforj and Niktimvo franchises.Actualización de narrativa • Mar 31
SNDX: MAXPIRe IPF Readout Will Shape Upside Beyond Core Franchise
Analysts have lifted their blended price target on Syndax Pharmaceuticals to $57, with the change largely tied to updated views on Revuforj and Niktimvo, as well as the upcoming Phase 2 MAXPIRe readout, which some see as an additional call option that is not fully reflected in the current share price. Analyst Commentary Street research on Syndax Pharmaceuticals in recent months has centered on how much value to assign to Revuforj and Niktimvo in existing refractory settings versus the potential upside from the MAXPIRe study in idiopathic pulmonary fibrosis.Seeking Alpha • Mar 18
Syndax Pharma: Two Drug Launches Fuel Transformational Growth
Summary Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to access a $5 billion+ AML market, with 1L Phase 3 trials as a major catalyst. Niktimvo's strong launch in GVHD and operational leverage support increasing collaboration revenue, with potential market doubling via frontline studies. I reiterate a "Strong Buy" rating as SNDX approaches profitability by 2027, supported by a solid balance sheet and significant TAM expansion opportunities. Read the full article on Seeking AlphaActualización de narrativa • Mar 17
SNDX: MAXPIRe IPF Readout Will Drive Future Repricing Potential
Analysts have lifted their average price target on Syndax Pharmaceuticals to a range anchored around recent Street moves toward $45 to $57, citing growing conviction in the potential contribution from Revuforj, Niktimvo and upcoming Niktimvo IPF Phase 2 MAXPIRe data, which some view as a "free call option" at current share levels. Analyst Commentary Recent research on Syndax Pharmaceuticals has focused on how much value the market may be assigning to Revuforj and Niktimvo in their current and potential indications, as well as the impact of upcoming Niktimvo idiopathic pulmonary fibrosis data from the Phase 2 MAXPIRe study.Actualización de narrativa • Mar 02
SNDX: Leukemia Drug Progress And Citi Upgrade Will Drive Future Repricing
Narrative update on Syndax Pharmaceuticals The analyst fair value estimate for Syndax Pharmaceuticals has shifted from $27.00 to $28.00, supported by recent price target increases from firms such as Citi and BofA as analysts factor in updated expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research on Syndax Pharmaceuticals has centered on adjustments to price targets and the assumptions behind them, including revenue outlook, profitability, and P/E expectations.Actualización de narrativa • Feb 16
SNDX: Expanded Leukemia Reach And Refined Risk Profile Will Support Long-Term Upside
Analysts have nudged their price target on Syndax Pharmaceuticals higher by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers behind the change. Analyst Commentary Analysts lifting their fair value assumptions on Syndax Pharmaceuticals are generally reacting to updated views on growth, profitability, and risk, which together support the modest US$1 move in the price target.Actualización de narrativa • Feb 02
SNDX: FDA Leukemia Progress And UBS Upgrade Will Drive Future Repricing
Narrative Update: Syndax Pharmaceuticals Analysts recently raised their price target on Syndax Pharmaceuticals shares to $38 from $35, citing updated assumptions for growth, profitability, and future P/E that have modestly adjusted their valuation outlook. Analyst Commentary Although the latest price target is now US$38, analysts are not uniformly positive and continue to highlight areas of uncertainty around how that valuation could be realized.Actualización de narrativa • Jan 19
SNDX: FDA Decision On Leukemia Therapy Will Drive Future Repricing Potential
Analysts have lifted their fair value estimate for Syndax Pharmaceuticals to US$27.00 from US$19.00. They cite higher Street price targets following recent FDA action on Revuforj and a willingness to use a richer future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.Actualización de narrativa • Jan 04
SNDX: Expanded Leukemia Approval Will Support Stronger Long Term Upside Potential
Analysts modestly raised their blended price target for Syndax Pharmaceuticals, reflecting recent upward revisions from $35 to $38 and from $26 to $27, as they point to supportive FDA developments and view recent stock weakness as overdone. Analyst Commentary Bullish analysts highlight that recent price target increases reflect confidence in Syndax Pharmaceuticals' ability to execute on its clinical and commercial strategy, even after market volatility following regulatory updates.Actualización de narrativa • Dec 18
SNDX: Expanded Leukemia Approval Will Drive Stronger Long Term Commercial Momentum
Analysts have nudged their average price target on Syndax Pharmaceuticals modestly higher, to about $39.31 per share from roughly $39.31, citing strengthened conviction in long term growth and profitability following supportive regulatory developments and recent target increases from multiple covering firms. Analyst Commentary Recent target increases and reiterated positive ratings underscore a growing confidence among coverage in Syndax Pharmaceuticals, particularly around its lead asset Revuforj and the companys ability to convert regulatory wins into durable revenue growth.Actualización de narrativa • Dec 04
SNDX: Expanded Leukemia Label Will Drive Stronger Long Term Commercial Momentum
The analyst price target for Syndax Pharmaceuticals has been raised by approximately $1 to about $39 per share, as analysts cite recent target increases across the Street and reaffirmed Buy ratings, supported by continued confidence in Revuforj's commercial outlook despite label-related concerns. Analyst Commentary Bullish analysts highlight that the recent price target increases, even if modest in absolute dollars, signal growing confidence in Syndax's execution and Revuforj's commercial ramp.Artículo de análisis • Nov 23
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up
Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shares have had a really impressive month, gaining 29% after a shaky...Actualización de narrativa • Nov 20
SNDX: New FDA Approval Will Drive Continued Momentum In Oncology Markets
The analyst price target for Syndax Pharmaceuticals has been revised downward by $0.54 to $38.31. Analysts factor in lower projected profit margins and slower revenue growth, despite ongoing industry optimism around the company's recent drug approvals and market positioning.Artículo de análisis • Nov 06
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
It's been a pretty great week for Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders, with its shares surging...Actualización de narrativa • Nov 05
SNDX: Recent FDA Approvals Will Expand Market Opportunity In AML Therapy
The analyst price target for Syndax Pharmaceuticals has increased from approximately $36.55 to $38.85. Analysts cite recent FDA approvals and positive strategic developments as key factors supporting the upward revision.Artículo de análisis • Aug 06
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking
NasdaqGS:SNDX 1 Year Share Price vs Fair Value Explore Syndax Pharmaceuticals's Fair Values from the Community and...Actualización de narrativa • Aug 06
Revuforj And Niktimvo Will Extend Precision Oncology Reach
Despite a sharp reduction in expected revenue growth, Syndax Pharmaceuticals’ future P/E has improved considerably, supporting a higher analyst price target, now revised up from $32.67 to $34.33. What's in the News Syndax Pharmaceuticals announced the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML), reviewed under the Real-Time Oncology Review (RTOR) program.Artículo de análisis • Aug 05
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • May 08
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results
Shareholders in Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) had a terrible week, as shares crashed 29% to US$9.99 in...Artículo de análisis • Apr 26
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nueva narrativa • Mar 24
FDA Approvals Will Expand AML And cGVHD Treatment Options
Recent FDA approvals and strategic collaborations position Syndax to significantly enhance revenue and address unmet clinical needs in oncology.Artículo de análisis • Feb 07
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 22
Syndax Looks Tantalizing, But Looks Can Be Deceptive
Summary Syndax Pharmaceuticals has two approved drugs, Axatilimab and Revumenib, but the stock has fallen 50% due to competitive pressures and market skepticism. Revumenib shows promise in treating KMT2A AML and mNPM1 AML, but faces stiff competition from Kura Oncology's superior efficacy data in mNPM1 AML. Axatilimab, approved for cGVHD, differentiates itself from other treatments but operates in a differentiated market with limited revenue potential. Despite a strong cash position and promising pipeline, market concerns about revenue potential and competition keep SNDX stock depressed. Read the full article on Seeking AlphaArtículo de análisis • Oct 14
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 20
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Summary Syndax Pharmaceuticals, Inc.'s stock is down 25% from recent highs, presenting a potential buying opportunity for aggressive investors as the company nears key inflection points. The company recently had its first drug it has developed with Incyte approved, and a wholly owned compound should be approved at the tail end of 2024. The stock enjoys strong analyst support, but is likely to raise additional capital in 2025. An updated analysis around Syndax Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 21
Syndax: Gearing Up For Launches
Summary Syndax Pharmaceuticals has upcoming Q3 PDUFAs for revumenib and axatilimab, both awarded priority review. Syndax pegs both upcoming PDUFAs as potential blockbusters once approved, with revumenib offering a larger revenue opportunity. Syndax's value as an investment depends on FDA approvals and successful commercialization of its molecules, making it a speculative high-risk investment. Read the full article on Seeking AlphaArtículo de análisis • Jun 20
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 28
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Summary Syndax Pharmaceuticals has two lead molecules in line for FDA review: revumenib for the treatment of acute leukemia and axatilimab for chronic graft-versus-host disease. Syndax is a speculative buy for those willing to take a risk on the FDA approval process. The approval and launch of revumenib in 2024 and the axatilimab deal with Incyte are important milestones to watch. Read the full article on Seeking AlphaArtículo de análisis • Mar 04
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 729 | 112 | 179 | 186 | 11 |
| 12/31/2027 | 540 | -6 | 68 | 70 | 12 |
| 12/31/2026 | 346 | -151 | -63 | -156 | 12 |
| 3/31/2026 | 217 | -243 | -278 | -278 | N/A |
| 12/31/2025 | 172 | -285 | -323 | -323 | N/A |
| 9/30/2025 | 111 | -312 | -311 | -311 | N/A |
| 6/30/2025 | 78 | -335 | -303 | -303 | N/A |
| 3/31/2025 | 44 | -331 | -287 | -287 | N/A |
| 12/31/2024 | 24 | -319 | -275 | -275 | N/A |
| 9/30/2024 | 16 | -297 | -259 | -259 | N/A |
| 6/30/2024 | 4 | -264 | -241 | -241 | N/A |
| 3/31/2024 | N/A | -241 | -205 | -205 | N/A |
| 12/31/2023 | N/A | -209 | -161 | -161 | N/A |
| 9/30/2023 | N/A | -176 | -142 | -142 | N/A |
| 6/30/2023 | N/A | -160 | -126 | -126 | N/A |
| 3/31/2023 | N/A | -153 | -131 | -131 | N/A |
| 12/31/2022 | N/A | -149 | -134 | -134 | N/A |
| 9/30/2022 | 127 | -14 | -10 | -10 | N/A |
| 6/30/2022 | 139 | 1 | -7 | -6 | N/A |
| 3/31/2022 | 139 | 15 | 10 | 10 | N/A |
| 12/31/2021 | 140 | 25 | 29 | 29 | N/A |
| 9/30/2021 | 14 | -92 | -87 | -87 | N/A |
| 6/30/2021 | 2 | -91 | -81 | -81 | N/A |
| 3/31/2021 | 2 | -86 | -78 | -78 | N/A |
| 12/31/2020 | 2 | -77 | -71 | -71 | N/A |
| 9/30/2020 | 2 | -71 | -68 | -68 | N/A |
| 6/30/2020 | 2 | -63 | -59 | -59 | N/A |
| 3/31/2020 | 2 | -61 | -50 | -50 | N/A |
| 12/31/2019 | 2 | -56 | N/A | -51 | N/A |
| 9/30/2019 | 2 | -61 | N/A | -53 | N/A |
| 6/30/2019 | 2 | -65 | N/A | -63 | N/A |
| 3/31/2019 | 2 | -69 | N/A | -65 | N/A |
| 12/31/2018 | 2 | -74 | N/A | -69 | N/A |
| 9/30/2018 | 2 | -74 | N/A | -66 | N/A |
| 6/30/2018 | 2 | -72 | N/A | -58 | N/A |
| 3/31/2018 | 2 | -67 | N/A | -55 | N/A |
| 12/31/2017 | 2 | -61 | N/A | -47 | N/A |
| 9/30/2017 | 1 | -53 | N/A | -45 | N/A |
| 6/30/2017 | 1 | -52 | N/A | -46 | N/A |
| 3/31/2017 | 1 | -47 | N/A | -41 | N/A |
| 12/31/2016 | 1 | -47 | N/A | -35 | N/A |
| 9/30/2016 | 1 | -45 | N/A | -29 | N/A |
| 6/30/2016 | 1 | -87 | N/A | -23 | N/A |
| 3/31/2016 | 1 | -105 | N/A | -20 | N/A |
| 12/31/2015 | 1 | -104 | N/A | -2 | N/A |
| 9/30/2015 | 0 | -100 | N/A | -2 | N/A |
| 6/30/2015 | 0 | -53 | N/A | 1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que SNDX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que SNDX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que SNDX sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (30.3% al año) de SNDX crezcan más rápidamente que los del mercado US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (30.3% al año) de SNDX crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de SNDX sea alta dentro de 3 años (35.3%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 13:16 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Syndax Pharmaceuticals, Inc. está cubierta por 27 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Jason Zemansky | BofA Global Research |